Italia markets closed

OPKO Health, Inc. (0KCS.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
3,8400-0,1100 (-2,78%)
Alla chiusura: 04:27PM GMT
Schermo intero
Chiusura precedente3,9500
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno3,8300 - 3,8800
Intervallo di 52 settimane3,8300 - 3,8800
Media VolumeN/D
Beta (5 anni mensile)1,70
Rapporto PE (ttm)32,54
EPS (ttm)0,1180
Prossima data utili16 feb 2022 - 21 feb 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    OPKO Health Announces the Passing of Director Dr. Richard Lerner

    MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D. passed away on December 2nd at the age of 83. Dr. Lerner had served as a Director of OPKO Health since 2007. The Board of Directors and staff of OPKO extend their deepest condolences to the Lerner family and express their gratitude for Dr. Lerner’s many contributions to OPKO and to the advancement of science. Dr. Lerner served as President of The Scripps Research Institute, a

  • GlobeNewswire

    OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

    MIAMI, Nov. 29, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 through December 2, 2021. A pre-recorded company fireside chat is available for registered attendees via the Piper Sandler conference site and at this link. Management will be available for one-on-one virtual meetings with investors on Wednesday, December 1st, which can be requested t

  • GlobeNewswire

    OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results

    Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Oct. 28, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2021. Business Highlights Health Canada approved NGENLA™ (somatrogon) injection for pediatric growth hormone deficiency. NGENLA is a once-weekly, long-acting recombinant human growth hormone, for the long-term treatment of pediatric patients who have growth failure due to an inadeq